Kymera Therapeutics (NASDAQ:KYMR) Trading 6.2% Higher – Time to Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price rose 6.2% during mid-day trading on Monday . The company traded as high as $27.03 and last traded at $27.59. Approximately 42,876 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 547,786 shares. The stock had previously closed at $25.97.

Analysts Set New Price Targets

KYMR has been the topic of a number of research analyst reports. Stephens restated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright increased their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Citigroup started coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company. Finally, Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Kymera Therapeutics Trading Up 6.0 %

The company has a market cap of $1.87 billion, a price-to-earnings ratio of -12.31 and a beta of 2.22. The stock has a 50 day moving average price of $30.15 and a two-hundred day moving average price of $38.79.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KYMR. Blue Trust Inc. boosted its holdings in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming bought a new stake in Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $55,000. KBC Group NV grew its position in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Kymera Therapeutics by 3,851.5% during the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company’s stock worth $183,000 after purchasing an additional 6,509 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.